The plasminogen activator system modulates sympathetic nerve function

Journal of Experimental Medicine

Volumn 203, Issue 9, 2006, Pages 2191-2200

  Schaefer, Ulrich ^a   Machida, Takuji ^a   Vorlova, Sandra ^b   Strickland, Sidney ^b   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; NORADRENALIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RISK; DRUG ACTIVITY; DRUG EFFECT; ELECTROSTIMULATION; EXOCYTOSIS; HEART ARRHYTHMIA; HEART DEATH; HUMAN; HUMAN CELL; ISCHEMIA; MALE; MOUSE; NERVE STIMULATION; NEUROBLASTOMA CELL; NEUROMODULATION; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN SECRETION; REPERFUSION INJURY; SWINE; SYMPATHETIC FUNCTION; SYMPATHETIC NERVE; SYNAPTOSOME;

ADRENERGIC FIBERS; ANIMALS; ELECTRIC STIMULATION; EXOCYTOSIS; GENE DELETION; GUINEA PIGS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; MYOCARDIUM; NEUROBLASTOMA; NEUROMUSCULAR JUNCTION; NOREPINEPHRINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPERFUSION INJURY; SYMPATHOMIMETICS; SYNAPTOSOMES; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED; VAS DEFERENS;

EID: 33748468238     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20060077     Document Type: Article

References (67)

1. Levin, E.G., and G.J. del Zoppo. 1994. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am. J. Pathol. 144:855-861.
2. Eijnden-Schrauwen, Y., T. Kooistra, R. E. de Vries, and J.J. Emeis. 1995. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood. 85:3510-3517.
3. Wang, Y., X. Jiang, A.R. Hand, C. Gilles, J. Kirk, R.E. Cone, and J. O'Rourke. 2002. Additional evidence that the sympathetic nervous system regulates the vessel wall release of tissue plasminogen activator. Blood Coagul. Fibrinolysis. 13:471-481.
4. O'Rourke, J., X. Jiang, Z. Hao, R.E. Cone, and A.R. Hand. 2005. Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J. Neurosci. Res. 79:727-733.
5. Collen, D. 1999. The plasminogen (fibrinolytic) system. Thromb. Haemost. 82:259-270.
6. Yakovlev, S., E. Makogonenko, N. Kurochkina, W. Nieuwenhuizen, K. Ingham, and L. Medved. 2000. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry. 39:15730-15741.
7. Medved, L., and W. Nieuwenhuizen. 2003. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb. Haemost. 89:409-419.
8. Potempa, J., E. Korzus, and J. Travis. 1994. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269:15957-15960.
9. Robbie, L.A., N.A. Booth, A.M. Croll, and B. Bennett. 1993. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb. Haemost. 70:301-306.
10. Peng, T., X. Jiang, Y.F. Wang, A. Hand, C. Gillies, R.E. Cone, and J. O'Rourke. 1999. Sympathectomy decreases and adrenergic stimulation increases the release of tissue plasminogen activator (t-PA) from blood vessels: functional evidence for a neurologic regulation of plasmin production within vessel walls and other tissue matrices. J. Neurosci. Res. 57:680-692.
11. Jiang, X., Y. Wang, A.R. Hand, C. Gillies, R.E. Cone, J. Kirk, and J. O'Rourke. 2002. Storage and release of tissue plasminogen activator by sympathetic axons in resistance vessel walls. Microvasc. Res. 64:438-447.
12. Jiang, X., A.R. Hand, S. Shen, R.E. Cone, and J. O'Rourke. 2003. Enhanced tissue plasminogen activator synthesis by the sympathetic neurons that innervate aging vessels. J. Neurosci. Res. 71:567-574.
13. Bashkov, G.V., I.Y. Sergeev, and N.A. Medvedeva. 1993. Role of sympathetic cholinergic pathway in the neurogenous control of tissue-type plasminogen activator release into the blood. Blood Coagul. Fibrinolysis. 4:993-998.
14. Jern, C., L. Selin, and S. Jern. 1994. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb. Haemost. 72:285-291.
15. Björkman, J.A., S. Jern, and C. Jern. 2003. Cardiac sympathetic nerve stimulation triggers coronary t-PA release. Arterioscler. Thromb. Vasc. Biol. 23:1091-1097.
16. Aspelin, T., M. Eriksen, A.K. Lindgaard, T. Lyberg, and A. Ilebekk. 2005. Cardiac fibrinolytic capacity is markedly increased after brief periods of local myocardial ischemia, but declines following successive periods in anesthetized pigs. J. Thromb. Haemost. 3:1947-1954.
17. Leprince, P., B. Rogister, P. Delree, J.M. Rigo, B. Andre, and G. Moonen. 1991. Modulation of proteolytic activity during neuritogenesis in the PC12 nerve cell: differential control of plasminogen activator and plasminogen activator inhibitor activities by nerve growth factor and dibutyryl-cyclic AMP. J. Neurochem. 57:665-674.
18. Pittman, R.N., and A.J. DiBenedetto. 1995. PC12 cells overexpressing tissue plasminogen activator regenerate neurites to a greater extent and migrate faster than control cells in complex extracellular matrix. J. Neurochem. 64:566-575.
19. Gualandris, A., T.E. Jones, S. Strickland, and S.E. Tsirka. 1996. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J. Neurosci. 16:2220-2225.
20. Parmer, R.J., M. Mahata, S. Mahata, M.T. Sebald, D.T. O'Connor, and L.A. Miles. 1997. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J. Biol. Chem. 272:1976-1982.
21. Parmer, R.J., and L.A. Miles. 1998. Targeting of tissue plasminogen activator to the regulated pathway of secretion. Trends Cardiovasc. Med. 8:306-312.
22. Lupu, F., D.A. Heim, F. Bachmann, M. Hurni, V.V. Kakkar, and E.K. Kruithof. 1995. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15:1444-1455.
23. Chen, Z.L., and S. Strickland. 1997. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 91:917-925.
24. Castellino, F.J., and V.A. Ploplis. 2005. Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93:647-654.
25. Melchor, J.P., and S. Strickland. 2005. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93:655-660.
26. Sneddon, P. 2000. Electrophysiology of autonomic neuromuscular transmission involving ATP. J. Auton. Nerv. Syst. 81:218-224.
27. Westfall, T.D., and D.P. Westfall. 2001. Pharmacological techniques for the in vitro study of the vas deferens. J. Pharmacol. Toxicol. Methods. 45:109-122.
28. Renatus, M., W. Bode, R. Huber, J. Sturzebecher, and M.T. Stubbs. 1998. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. J. Med. Chem. 41:5445-5456.
29. Lambrecht, G., T. Friebe, U. Grimm, U. Windscheif, E. Bungardt, C. Hildebrandt, H.G. Baumert, G. Spatz-Kumbel, and E. Mutschler. 1992. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur. J. Pharmacol. 217:217-219.
30. Hess, H.J. 1975. Prazosin: biochemistry and structure-activity studies. Postgrad. Med. Spec No:9-17.
31. 2-receptor activation augments norepinephrine exocytosis from cardiac sympathetic nerve endings. Mediation by autocrine/paracrine mechanisms. Circ. Res. 81:774-784.
32. Verheijen, J.H., E. Mullaart, G.T. Chang, C. Kluft, and G. Wijngaards. 1982. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb. Haemost. 48:266-269.
33. Vaughan, P.F., C. Peers, and J.H. Walker. 1995. The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. Gen. Pharmacol. 26:1191-1201.
34. Sher, E., E. Biancardi, M. Passafaro, and F. Clementi. 1991. Physiopathology of neuronal voltage-operated calcium channels. FASEB J. 5:2677-2683.
35. 1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 286:H1448-H1454.
36. 3-receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J. Pharmacol. Exp. Ther. 283:494-500.
37. 3-receptors: a new frontier in myocardial ischemia. J. Pharmacol. Exp. Ther. 292:825-830.
38. Sesti, C., M. Koyama, M.J. Broekman, A.J. Marcus, and R. Levi. 2003. Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia. J. Pharmacol. Exp. Ther. 306:238-244.
39. Podrid, P.J., T. Fuchs, and R. Candinas. 1990. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation. 82: I103-I113.
40. Selwyn, A.P., and E. Braunwald. 2001. Ischemic heart disease. In Harrison's Principles of Internal Medicine. E. Braunwald, A.S. Fauci, D.L. Kasper, S.L. Hauser, D.L. Longo, and J.L. Jameson, editors. McGraw-Hill, New York. 1399-1410.
41. Wall, U., C. Jern, and S. Jern. 1997. High capacity for tissue-type plasminogen activator release from vascular endothelium in vivo. J. Hypertens. 15:1641-1647.
42. Huber, D., E.M. Cramer, J.E. Kaufmann, P. Meda, J.M. Masse, E.K. Kruithof, and U.M. Vischer. 2002. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood. 99:3637-3645.
43. Cipolla, M.J., N. Lessov, W.M. Clark, and E.C. Haley Jr. 2000. Postischemic attenuation of cerebral artery reactivity is increased in the presence of tissue plasminogen activator. Stroke. 31:940-945.
44. Schömig, A., T. Kurz, G. Richardt, and E. Schomig. 1988. Neuronal sodium homoeostasis and axoplasmic amine concentration determine calcium-independent noradrenaline release in normoxic and ischemic rat heart. Circ. Res. 63:214-226.
45. Dart, A.M., and R.A. Riemersma. 1989. Effects of acidosis on anoxic and exocytotic noradrenaline release from the heart. J. Mol. Cell. Cardiol. 21:75-83.
46. Benchenane, K., V. Berezowski, C. Ali, M. Fernandez-Monreal, J.P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E.T. MacKenzie, G. Bu, et al. 2005. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation. 111:2241-2249.
47. Madison, E.L., G.S. Coombs, and D.R. Corey. 1995. Substrate specificity of tissue type plasminogen activator. Characterization of the fibrin independent specificity of t-PA for plasminogen. J. Biol. Chem. 270:7558-7562.
48. Hajjar, K.A. 1991. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen. J. Biol. Chem. 266:21962-21970.
49. Fernandez-Monreal, M., J.P. Lopez-Atalaya, K. Benchenane, M. Cacquevel, F. Dulin, J.P. Le Caer, J. Rossier, A.C. Jarrige, E.T. MacKenzie, N. Colloc'h, C. Ali, and D. Vivien. 2004. Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling. J. Biol.Chem. 279:50850-50856.
50. Winnerkvist, A., B. Wiman, G. Valen, and J. Vaage. 1996. Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts. Thromb. Res. 82:533-542.
51. Osterlund, B., B. Andersson, S. Haggmark, C. Jern, G. Johansson, H. Seeman-Lodding, and B. Biber. 2002. Myocardial ischemia induces coronary t-PA release in the pig. Acta. Anaesthesiol. Scand. 46:271-278.
52. Pretorius, M., D. Rosenbaum, D.E. Vaughan, and N.J. Brown. 2003. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 107:579-585.
53. Steins, M.B., T. Padro, C.X. Li, R.M. Mesters, H. Ostermann, D. Hammel, H.H. Scheld, W.E. Berdel, and J. Kienast. 1999. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis. 145:173-180.
54. Olofsson, B.O., G. Dahlen, and T.K. Nilsson. 1989. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur. Heart J. 10:77-82.
55. Ridker, P.M., D.E. Vaughan, M.J. Stampfer, J.E. Manson, and C.H. Hennekens. 1993. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 341:1165-1168.
56. Thompson, S.G., J. Kienast, S.D. Pyke, F. Haverkate, and J.C. van de Loo. 1995. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332:635-641.
57. Linnik, W., J.E. Tintinalli, and R. Ramos. 1989. Associated reactions during and immediately after rtPA infusion. Ann. Emerg. Med. 18: 234-239.
58. Mehta, J.L., W.W. Nichols, T.G. Saldeen, V.K. Chandna, F.A. Nicolini, D.L. Lawson, and M.F. ter Riet. 1990. Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator. J. Cardiovasc. Pharmacol. 16:112-120.
59. Lepley-Frey, D. 1991. Dysrhythmias and blood pressure changes associated with thrombolysis. Heart Lung. 20:335-341.
60. Wilcox, R.G., J. Eastgate, E. Harrison, and A.M. Skene. 1991. Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction. Br. Heart J. 65:4-8.
61. Newby, K.H., T. Thompson, A. Stebbins, E.J. Topol, R.M. Califf, and A. Natale. 1998. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation. 98:2567-2573.
62. Wang, Y.F., S.E. Tsirka, S. Strickland, P.E. Stieg, S.G. Soriano, and S.A. Lipton. 1998. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4:228-231.
63. Carmeliet, P., J.M. Stassen, L. Schoonjans, B. Ream, J.J. van den Oord, M. De Mol, R.C. Mulligan, and D. Collen. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92:2756-2760.
64. Carmeliet, P., R.C. Mulligan, and D. Collen. 1994. Transgenic animals as tools for the study of fibrinolysis in vivo. J. Intern. Med. 236:455-459.
65. 3H]noradrenaline from human neuroblastoma cells, SH-SY5Y. J. Neurochem. 56:1810-1815.
66. 3 receptors. Mol. Pharmacol. 63: 378-382.
67. Walker, M.J., M.J. Curtis, D.J. Hearse, R.W. Campbell, M.J. Janse, D.M. Yellon, S.M. Cobbe, S.J. Coker, J.B. Harness, D.W. Harron, et al. 1988. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc. Res. 22:447-455.